Eurand Completes Bioavailability Study of Zentase

Eurand has finished the gastrointestinal bioavailability study of Zentase, a treatment for exocrine pancreatic insufficiency (EPI).

Zentase is a porcine-derived pancreatic enzyme replacement therapy being developed to treat EPI, a condition associated with cystic fibrosis, chronic pancreatitis and other conditions.

The study was conducted in chronic pancreatitis patients in the U.S. and the results will be included in Zentase’s new drug application (NDA), according to Eurand. 

The company began its rolling NDA submission in June and has been granted fast-track designation by the FDA.